Product logins

Find logins to all Clarivate products below.


John Lebbos

Partner, Commercial Strategy Consulting

John Lebbos, MD is a Partner in Clarivate’s Commercial Strategy Consulting team.​​​

He is currently a practice leader in Product and Market Opportunity Assessments & Strategy and has over 20 years of experience supporting clients with product and therapeutic area strategy, functional patient journey analysis, opportunity and market assessments, disease area analysis, sales forecasting, and portfolio planning/strategy.​​

Formerly a Vice President in DRG’s infectious disease syndicated research group, Dr. Lebbos led the Infectious Disease research team and has had over 20 years of experience conducting market analysis, opportunity assessments and prioritization and product strategy. ​​

Dr. Lebbos received his medical degree from the University of Massachusetts. Prior to pursuing his medical degree, he attended Tufts University where he graduated summa cum laude in chemical engineering.


arrow_forward
Get in touch with John

Related resources

支付方愿意为便利性买单的市场准入“最佳切入点” 支付方愿意为便利性买单的市场准入“最佳切入点”
Blog June 3, 2026
支付方愿意为便利性买单的市场准入“最佳切入点”
医疗保险 定价 市场准入 真实世界数据 美国市场 药政法规
2026 年值得关注的 5 大医疗技术趋势 2026 年值得关注的 5 大医疗技术趋势
Blog May 28, 2026
2026 年值得关注的 5 大医疗技术趋势
AI/机器学习 GLP-1 医疗技术 带量采购(VBP) 日间手术中心(ASC)
《2026年最值得关注的药物》问答:礼来的下一代减肥药 《2026年最值得关注的药物》问答:礼来的下一代减肥药
Blog March 26, 2026
《2026年最值得关注的药物》问答:礼来的下一代减肥药
GLP-1 最值得关注的药物
为何长寿研究可能成为生物制药的下一个风口:当科学与商业的交汇 为何长寿研究可能成为生物制药的下一个风口:当科学与商业的交汇
Blog March 2, 2026
为何长寿研究可能成为生物制药的下一个风口:当科学与商业的交汇
AI/机器学习 GLP-1 临床试验 交易 药政法规 衰老生物学